[go: up one dir, main page]

AR107834A1 - ANTIBODIES THAT JOIN THE TUMOR NECROSIS FACTOR INDICATED BY GLUCOCORTICOIDS (GITR), METHODS AND USES - Google Patents

ANTIBODIES THAT JOIN THE TUMOR NECROSIS FACTOR INDICATED BY GLUCOCORTICOIDS (GITR), METHODS AND USES

Info

Publication number
AR107834A1
AR107834A1 ARP170100580A ARP170100580A AR107834A1 AR 107834 A1 AR107834 A1 AR 107834A1 AR P170100580 A ARP170100580 A AR P170100580A AR P170100580 A ARP170100580 A AR P170100580A AR 107834 A1 AR107834 A1 AR 107834A1
Authority
AR
Argentina
Prior art keywords
antibodies
gitr
methods
glucocorticoids
join
Prior art date
Application number
ARP170100580A
Other languages
Spanish (es)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR107834A1 publication Critical patent/AR107834A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se proporcionan anticuerpos que se unen de manera específica a GITR. Además, se describen los polinucleótidos relacionados que tienen la capacidad de codificar los anticuerpos específicos para GITR o fragmentos de unión al antígeno proporcionados, las células que expresan los anticuerpos o fragmentos de unión al antígeno proporcionados, así como los vectores asociados y los anticuerpos o fragmentos de unión al antígeno etiquetados de forma detectable. Además, se describen los métodos para usar los anticuerpos proporcionados. Por ejemplo, los anticuerpos proporcionados pueden usarse para aumentar una respuesta inmune en un sujeto contra el cáncer.Antibodies that specifically bind GITR are provided herein. In addition, related polynucleotides that have the ability to encode GITR-specific antibodies or antigen-binding fragments provided, cells expressing the antibodies or antigen-binding fragments provided, as well as associated vectors and antibodies or fragments are described binding to the antigen labeled detectably. In addition, methods for using the antibodies provided are described. For example, the antibodies provided can be used to increase an immune response in a subject against cancer.

ARP170100580A 2016-03-08 2017-03-08 ANTIBODIES THAT JOIN THE TUMOR NECROSIS FACTOR INDICATED BY GLUCOCORTICOIDS (GITR), METHODS AND USES AR107834A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201661305270P 2016-03-08 2016-03-08

Publications (1)

Publication Number Publication Date
AR107834A1 true AR107834A1 (en) 2018-06-13

Family

ID=62683533

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100580A AR107834A1 (en) 2016-03-08 2017-03-08 ANTIBODIES THAT JOIN THE TUMOR NECROSIS FACTOR INDICATED BY GLUCOCORTICOIDS (GITR), METHODS AND USES

Country Status (1)

Country Link
AR (1) AR107834A1 (en)

Similar Documents

Publication Publication Date Title
UY36974A (en) ANTI-IL1RAP ANTIBODIES, BINDING SPECIFIC MOLECULES THAT JOIN IL1RAP AND CD3, AND USES OF THESE
UY37340A (en) GPRC5D ANTIANTICBODIES, BIO-SPECIFIC ANTIGEN BINDING MOLECULES THAT JOIN GPRC5D AND CD3, AND USES OF THESE
CR20170079A (en) UNION AGENTS TO CD123 AND USES OF THESE
UY36859A (en) ANTI-BCMA ANTIBODIES, MOLECULES OF UNION TO BIESPECTIFIC ANTIGENS THAT JOIN BCMA AND CD3, AND USES OF THESE
MX419976B (en) TGFB ANTIBODIES, METHODS, AND USES
CO2018000887A2 (en) Bispecific antibody constructs that bind to egfrviii and cd3
ECSP17083779A (en) IMMUNORECEPTOR BINDING AGENTS OF T-CELLS WITH GI DOMAINS AND INHIBITION MOTIVES BASED ON IMMUNORECEPTOR TYROSINE (TIGIT) AND USES THEREOF
NI201800061A (en) PD1 AND / OR LAG3 LINKS
CO2018000976A2 (en) Antibody constructs for cd70 and cd3
NI201800062A (en) CTLA4 LINKS
MX2017002205A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment.
MX2017001008A (en) CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANCIENT CD33.
ECSP19011185A (en) Bispecific antibody-like binding proteins that specifically bind CD3 and CD123
CO2018000882A2 (en) Antibody constructs for flt3 and cd3
CL2019002626A1 (en) Anti-par2 antibodies and their uses.
MX2018005546A (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND TIM-3 AND THEIR USES.
MX2018004114A (en) THERAPEUTIC COMPOUNDS AND METHODS.
CR20150575A (en) PAC1 HUMAN ANTIBODIES
MX2017001011A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor.
MX2016015456A (en) ANTIBODIES AGAINST THE RECEIVER OF THE TUMOR NECROSIS FACTOR INDICATED BY GLUCOCORTICOIDS (GITR) AND ITS USES.
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
MX2015010836A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor.
UY35718A (en) ANTI-CSF-1R ANTIBODIES: EXPRESSION METHODS OF THE SAME.
MX2016005956A (en) SPECIFIC ANTIBODIES FOR FCRN.
PH12018501902A1 (en) Gitr antibodies, methods, and uses

Legal Events

Date Code Title Description
FA Abandonment or withdrawal